|
1) Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-72
|
|
|
|
2) 日本腎臓学会. エビデンスに基づくCKD診療ガイドライン2009. 東京: 東京医学社; 2009. p.87-104
|
|
|
|
|
|
3) Poitout V, Amyot J, Semache M, et al. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta. 2010; 1801: 289-98
|
|
|
|
|
|
4) Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes: U. K. Prospective Diabetes Study 74. Diabetes. 2006; 55: 1832-9
|
|
|
|
|
|
5) Appel GB, Radhakrishnan J, Avram MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003; 26: 1402-7
|
|
|
|
|
|
6) Tolonen N, Forsblom C, Thorn L, et al. Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. Diabetologia. 2009; 52: 2522-30
|
|
|
|
|
|
7) Maeda S, Kobayashi MA, Araki S, et al. A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS genetics. 2010; 6: e1000842
|
|
|
|
|
|
8) Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348: 383-93
|
|
|
|
|
|
9) Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358: 580-91
|
|
|
|
|
|
10) Araki S, Haneda M, Sugimoto T, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes. 2005; 54: 2983-7
|
|
|
|
|
|
11) Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006; 17: 2006-16
|
|
|
|
|
|
12) Krane V, Wanner C. Statins, inflammation and kidney disease. Nat Rev Nephrol. 2011; 7: 385-97
|
|
|
|
|
|
13) Rutledge JC, Ng KF, Aung HH, et al. Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol. 2010; 6: 361-70
|
|
|
|
|
|
14) Eto M, Saito M, Okada M, et al. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis. 2002; 40: 243-51
|
|
|
|
|
|
15) Lee HS, Song CY. Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis. Am J Nephrol. 2009; 29: 62-70
|
|
|
|
|
|
16) Wang L, Sapuri-Butti AR, Aung HH, et al. Triglyceride-rich lipoprotein lipolysis increases aggregation of endothelial cell membrane microdomains and produces reactive oxygen species. Am J Physiol. 2008; 29: H237-44
|
|
|
|
|
|
17) Redgrave TG. Chylomicron metabolism. Biochem Soc Trans. 2004; 32: 79-82
|
|
|
|
|
|
18) Veiraiah A. Hyperglycemia, lipoprotein glycation, and vascular disease. Angiology. 2005; 56: 431-8
|
|
|
|
|
|
19) Kuwabara A, Satoh M, Tomita N, et al. Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats. Diabetologia. 2010; 53: 2056-65
|
|
|
|
|
|
20) Motoyoshi Y, Matsusaka T, Saito A, et al. Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria. Kidney Int. 2008; 74: 1262-9
|
|
|
|
|
|
21) Tanaka Y, Kume S, Araki S, et al. Fenofibrate, a PPARalpha agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int. 2011; 79: 871-82
|
|
|
|
|
|
22) Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999; 340: 115-26
|
|
|
|
|
|
23) Furuta T, Saito T, Ootaka T, et al. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis. 1993; 21: 480-5
|
|
|
|
|
|
24) Usui HK, Shikata K, Sasaki M, et al. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes. 2007; 56: 363-72
|
|
|
|
|
|
25) Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366: 1849-61
|
|
|
|
|
|
26) Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010; 363: 2406-15
|
|
|
|
|
|
27) DeNicola GM, Karreth FA, Humpton TJ, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011; 475: 106-9
|
|
|
|
|
|
28) Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011(in press)
|
|
|
|
|